WO2004006663A1 - 肝硬変モデル動物およびその作製方法 - Google Patents
肝硬変モデル動物およびその作製方法 Download PDFInfo
- Publication number
- WO2004006663A1 WO2004006663A1 PCT/JP2003/008939 JP0308939W WO2004006663A1 WO 2004006663 A1 WO2004006663 A1 WO 2004006663A1 JP 0308939 W JP0308939 W JP 0308939W WO 2004006663 A1 WO2004006663 A1 WO 2004006663A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- animal
- cirrhosis
- liver tissue
- tissue
- model animal
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 125
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 109
- 238000000034 method Methods 0.000 title description 14
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 76
- 210000003734 kidney Anatomy 0.000 claims abstract description 29
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 17
- 230000002950 deficient Effects 0.000 claims abstract description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 97
- 230000007882 cirrhosis Effects 0.000 claims description 97
- 210000001519 tissue Anatomy 0.000 claims description 31
- 230000028993 immune response Effects 0.000 claims description 30
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000003814 drug Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 239000002775 capsule Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000003195 fascia Anatomy 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
Definitions
- the present invention relates to a model animal for cirrhosis and a method for producing the same, and more particularly to a cirrhosis model animal having human liver tissue that has developed cirrhosis and a method for producing the same.
- Cirrhosis is a diffuse disease of the liver that leads to increased fiber production and nodular regeneration of residual hepatocytes in the liver due to persistent hepatocyte death.
- causes include infection (hepatitis virus, parasites), alcohol, biliary depression, hepatic depression, nutritional disorders, poisoning, metabolic abnormalities, autoimmunity, etc. These cause chronic hepatitis to cirrhosis. There are many things.
- Cirrhosis is an irreversible liver degenerative disease that causes various liver dysfunctions. In addition, cirrhosis often develops into liver cancer and can be fatal, so effective treatment is awaited. However, at present, it has been experimentally demonstrated that administration of liver regeneration factor HGF (also referred to as “hepatocyte growth factor”) by gene therapy, despite the large number of patients that are said to be national disease, has been experimentally improved. There is no definitive cure, only as indicated.
- HGF also referred to as “hepatocyte growth factor”
- liver tissue has been destroyed by oral administration of carbon tetrachloride to mice and rats. Although this model animal is suitable for the follow-up of liver regeneration, it does not have true cirrhosis tissue, and thus is an obstacle to developing therapeutic methods and therapeutic agents.
- the present invention has been made in view of the above problems, and an object of the present invention is to provide a cirrhosis model animal having liver tissue that actually developed cirrhosis and a method for producing the same. Disclosure of the invention
- the present inventors have intensively studied a model animal having cirrhosis and a method for producing the same.
- natural killer cell-dependent rejection was effectively suppressed by preliminarily treating an immunodeficient mouse (skid mouse: scidmouse) with an anti-asialo GM 1. antibody.
- skid mouse skid mouse: scidmouse
- anti-asialo GM 1. antibody an immunodeficient mouse
- they have found that human liver tissue derived from a cirrhosis patient can be transplanted under the kidney capsule of the above-described immunodeficient mouse and maintained for a long period of time, and have completed the present invention.
- the cirrhosis model animal of the present invention is characterized in that liver tissue of a human who has developed cirrhosis is transplanted into a tissue of an animal.
- liver tissue that has developed cirrhosis is engrafted in the animal.
- engraft liver tissue means that the transplanted liver tissue functions in the body without necrosis, and that the liver tissue is transplanted into a liver cirrhosis model. It means that things survive.
- the cirrhosis model animal obtained in this way is a new model animal that has never been produced. Therefore, the cirrhosis model animal according to the present invention has a liver tissue of a human who actually developed cirrhosis, unlike a conventional liver tissue in which the liver tissue was destroyed, so that the pathological analysis of cirrhosis was performed. And the development of remedies for it, and the improvement of treatment methods. It can prevent the progression of cirrhosis to liver cancer, and plays an important role in preventing these diseases.
- the tissue of the animal into which the liver tissue is transplanted is not particularly limited, but is preferably a tissue having a high blood flow so that the liver tissue is not necrotic due to ischemia.
- Such tissues include, for example, kidney, liver, spleen, muscle and the like.
- the liver tissue be transplanted into the kidney of the animal, more specifically, under the kidney capsule.
- engraftment into the kidney can achieve engraftment in a relatively short time (about one week).
- the animal is preferably an immunodeficient animal.
- immunodeficient animal refers to a part of the cellular elements that make up the immune system, and that a certain state is in an immunodeficient state in which the normal immune system is damaged due to some defect or dysfunction. means. In other words, it means that innate immunity and / or acquired immunity are suppressed so that the transplanted liver tissue will survive in the animal.
- the above-described immunodeficient animals are immunodeficient. It can be paraphrased as an animal.
- the immunodeficient animal preferably lacks some or all of the immunocompetent cells and factors involved in the immune response.
- the above-described immunodeficient animal preferably lacks an immune response ability dependent on T cells and Z or B cells, and further has an immune response ability dependent on natural killer cells (NK cells). More preferably (or the immune response ability is suppressed). It is thought that deficiency of immunocompetent cells and many factors involved in the immune response would suppress the immune response depending on the cells or factors and reduce rejection when transplanting liver tissue.
- NK cells natural killer cells
- the above-mentioned immunodeficient animals include, for example, nude animals lacking the thymus and lacking ⁇ cell-dependent immune response ability, and B cells in addition to lacking immune response ability in nude animals.
- examples thereof include a skid animal lacking a dependent immune response ability and an animal lacking a NK cell-dependent immune response ability in addition to a lack of immune response ability in a skid animal.
- One of the above-mentioned immunodeficient animals a mouse deficient in the immune response ability depending on T cells, B cells and NK cells, can be prepared by administering an anti-asialo GM1 antibody to a commonly used skid mouse. Can be made. Gash mouth G M1 is a protein specifically expressed in mouse NK cells. Therefore, administration of an anti-Asialo GM1 antibody to a skid mouse can result in a loss of NK cell-dependent immune response in addition to a loss of T-cell and B-cell dependent immune response.
- the above-mentioned animal is not particularly limited.
- mice, rats, and egrets are more preferable for use as experimental animals, and mice can be obtained in a relatively short period of time (about one week) and can be obtained at low cost.
- mice can be obtained in a relatively short period of time (about one week) and can be obtained at low cost. Particularly preferred.
- the liver tissue of a human who has developed cirrhosis is preferably classified as Child A in the Child classification, which is a classification of the severity of cirrhosis.
- the liver tissue of a human transplanted to obtain the above cirrhosis model animal preferably has a mild degree of cirrhosis, and for severe cirrhosis tissue classified as C, It is difficult to transplant.
- the cirrhosis tissue is mild enough to be classified as Child A, the survival rate of liver tissue in a cirrhosis model animal can be increased.
- the cirrhosis model animal according to the present invention as described above is obtained by transplanting the liver tissue having cirrhosis into the tissue of an immunodeficient animal in which the immune response ability of the animal has been lost, preferably under the renal capsule. It can be produced by engraftment. '
- cirrhosis tissue can be engrafted in the model animal body with a high probability and can be maintained for a long period of time. Therefore, it is possible to easily produce a cirrhosis model animal useful for the development of a treatment method and a therapeutic drug for cirrhosis.
- Cirrhosis model animal of the present invention and method for producing the same
- the cirrhosis model animal according to the present invention is obtained by transplanting the liver tissue of a human with cirrhosis into the body of the animal and engrafting the liver tissue in the body. That is, the cirrhosis model animal is obtained by transplanting a human liver tissue excised from a patient who has developed cirrhosis into another animal and engrafting the human liver tissue in the animal body. .
- human liver tissue which is a sample, can be easily obtained because hepatectomies are performed as treatment for hepatocellular carcinoma even in general hospitals and the number of patients is large.
- the above-mentioned “human liver tissue” is preferably one in which the degree of development of cirrhosis is mild.
- the “human liver tissue” is preferably a child A cirrhosis tissue. Transplantation of severe cirrhosis tissue classified as Child C seems to be difficult.
- the liver tissue to be transplanted may be normal liver tissue derived from a patient without cirrhosis, and in this case, the normal liver tissue is transplanted into an animal tissue described below to be a model animal, and Cirrhosis may be caused in normal liver tissue transplanted into a model animal.
- the “human liver tissue” described above may be transplanted with a piece of tissue from which liver tissue that has developed cirrhosis is removed, or the tissue piece may be cultured in the same individual or another organism in vivo. (vi vo), or may be a culture in vitro.
- the above-mentioned ⁇ human liver tissue '' was extracted from a liver cirrhosis patient. Afterwards, it is stored in ice-cooled culture medium (eg cell culture medium, physiological saline, etc.) Is preferred.
- the liver tissue to be transplanted varies depending on the size of the transplanted individual.For example, when transplanting into mice and rats, it is preferable that the liver tissue be resected to an appropriate size of about 2 mm square. .
- the tissue of the animal into which the sample is transplanted is not particularly limited as long as the sample can survive, but is preferably a tissue with a high blood flow so that the transplanted liver tissue is not necrotic due to ischemia.
- tissue include kidney, liver, spleen, and muscle.
- the liver tissue be transplanted into the kidney of the animal, more specifically, under the kidney capsule. “Transplanting under the kidney capsule” means that the capsule of the kidney to be transplanted is incised, and liver tissue is inserted into the incision.
- tissue of the animal may be a tissue that is unlikely to cause a rejection reaction with the sample, such as the conjunctiva of the eye.
- the sample and the tissue of the animal can be obtained by a technique using an immunodeficient animal in which the immune response function of the animal has been lost. Rejection reaction can be suppressed.
- ⁇ '' The above-described immunodeficient animals are in an immunodeficient state due to abnormalities of immunocompetent cells, abnormalities of genes such as immune response genes, administration of drugs such as immunosuppressants or physicochemical factors such as X-ray irradiation. Means an animal. Such an immunodeficient animal can be obtained by mutation or artificial creation.
- the method for artificially producing an immunosuppressed animal is not particularly limited, but the immunity can be controlled by genetic engineering techniques or drug administration.
- Part or all of one or more of cells or factors involved in the immune response (specifically, phagocytes such as B cells, T cells, NK cells, macrophages, complement, etc.) It can be manufactured by causing anomalies in the surface. If the number of immunocompetent cells or immune response factors that cause an abnormality is large, the immune response ability depending on them can be lost, and rejection when liver tissue is transplanted into an animal can be further reduced. Therefore, even a liver tissue derived from a human can be efficiently engrafted to the above-described immunodeficient animal.
- Examples of the immunodeficient animal include a nude animal lacking a T cell-dependent immune response ability, a skid animal lacking a T cell and B cell-dependent immune response ability, and a skid animal as described in Examples below. Examples of such animals include those that have lost NK cell-dependent immune response by administering an anti-asia GM1 antibody to the animals.
- the anti-Asialo GM1 antibody is an antibody that uses the asia GM1 protein specifically expressed in mouse NK cells as an antigen, and binds to NK cells by specifically binding to the protein. It lacks the dependent immune response ability. ⁇ 'In addition, in order to impair the immune response ability involving NK cells in animals other than mice, irradiation or a large amount of an immunosuppressant may be administered.
- the transplantation of the sample depends on the animal to be transplanted and its tissue, but can be performed by a conventionally known general method. For example, when implanting under the kidney capsule of a mouse as in the examples described below, the mouse is anesthetized, the laparotomy is performed, the kidney is exposed, and the liver tissue of the sample is introduced under the kidney capsule.
- the transplant may be performed by suturing the muscular layer and the skin in one layer.
- whether the transplanted human liver tissue has survived can be determined by HE staining the transplanted liver tissue. If HE staining confirms that it is alive, it can be determined that the transplanted human liver tissue has survived. On the other hand, in the tissue where engraftment has not been obtained, the cell structure is completely muddy, so that it can be easily determined.
- a determination method other than the above there is a method of measuring proteins synthesized in human hepatocytes, such as human albumin, human prealbumin, and ProteneC, by the ELISA method, the Western blot method, and the like.
- a liver-derived cirrhosis tissue can be transplanted to produce a cirrhosis model animal showing the pathology of cirrhosis.
- This cirrhosis model animal is a model animal having a disease state closer to that of a cirrhosis patient than a conventional model animal in which liver tissue has been ruptured, and thus can greatly contribute to the development of a treatment method and a therapeutic drug for cirrhosis. High.
- disease model animals with a certain disease state are closer to actual clinical symptoms than healthy animals. Therefore, it is preferable from the viewpoint of efficacy evaluation to conduct a test using a disease model animal having a certain disease state instead of a healthy animal. Therefore, such cirrhosis model animals play an important role as experimental animals in elucidating the causes of human diseases, and in developing techniques for diagnosis, prevention and treatment.
- the cirrhosis model animal obtained by the preparation method described in (1) above is as follows. 8939
- Liver tissue from humans with cirrhosis can be passaged in animals (especially mice that are easy to use as experimental animals), and a model animal showing the pathology of human cirrhosis can be obtained. -One-.
- liver tissue from a patient into the kidney of a cirrhosis model animal By transplanting liver tissue from a patient into the kidney of a cirrhosis model animal, a) the kidney of the cirrhosis model animal can be easily distinguished from the transplanted tissue. B) The left, right, or upper part of the kidney of the same individual It can be transplanted separately in the middle, lower, etc. Therefore, the effects of drugs under the same conditions are compared it can.
- a cirrhosis model animal was prepared using a skid mouse (scidmouse) deficient in T cells and B cells. The procedure is shown below.
- BALB mice were used as the above-mentioned skid mice.
- the above-mentioned skid mouse was pretreated with an anti-asialo GM1 antibody (manufactured by Cedarlane, model number: CL8955, name: Ranbbit Ant i-Mouse / Rat AsialoGMl Polyclonal Ant ibody) 20 days before transplantation. ⁇ g and then 20 ⁇ g intraperitoneally prior to laparotomy on the day of transplantation. For comparison, some skid mice were not administered the anti-Assaro GM1 antibody.
- Liver tissue removed from a cirrhosis patient was used as the liver tissue of a human with cirrhosis.
- the liver tissue was excised to a size of several centimeters after extraction and stored in an ice-cooled culture solution.
- the above-mentioned skid mouse was injected with an anesthetic (100 cc of physiological saline plus 4 cc of nembutal) containing Nembutal (manufactured by Banyu Pharmaceutical). 1 cc was administered intraperitoneally using a device (2.5 cc, needle 27 G) and anesthetized. With a 27 G needle, the intestinal tract escapes even if the mouse is stabbed vertically into the abdominal wall of the mouse, allowing injection without damaging the intestinal tract.
- the animated skid mouse had its limbs fixed with vinyl tape and a midline incision in the abdomen with scissors. At this time, the skin and fascia (fascia) were separately incised so as not to damage the intestinal tract and the like.
- the skid mouse was set with a mouse retractor and the intestinal tract was separated using a cotton swab or a sessile to expose the kidney.
- bleeding is responded by pressing with a cotton swab.
- a cotton swab was inserted into the back of the kidney, and the kidney was prolapsed.
- the kidney capsule was grasped with a microscopic sessile and a small incision was made.
- the liver tissue stored in the culture solution was excised into small pieces of about 2 mm square, and a small piece of the liver tissue was inserted under the incised kidney capsule while holding the kidney capsule of the skid mouse with a sessie.
- the intestinal tract is returned to the abdominal cavity.
- the incision in the abdomen was sutured using sutures (3-0 silk).
- the suture was performed on each of the two layers of skin and fascia. After that, the above-mentioned skid mouse was transferred to another gauge and awakened from anesthesia in about 2 hours.
- the survival rate of the cirrhosis model animal prepared in Example 1 was 100%. That is, all mice awakened from anesthesia survived.
- the above-mentioned anti-Asialo GM1 antibody was further administered on the 5th and 10th days after the transplantation.
- a cirrhosis model animal having a liver tissue of a human with cirrhosis can be obtained with a high probability.
- This cirrhosis model animal differs from a conventional experimental animal for cirrhosis and is actually a transplanted human cirrhosis tissue. Therefore, it can be suitably used for a screening test of a drug for diagnosing cirrhosis and a drug for preventing and / or treating cirrhosis, and is expected to greatly facilitate the development of a drug for treating cirrhosis.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020057000372A KR100676010B1 (ko) | 2002-07-16 | 2003-07-14 | 간경변 모델동물 및 그 제작방법 |
EP03741384A EP1552739A4 (en) | 2002-07-16 | 2003-07-14 | MODEL animal for liver cirrhosis and method for its construction |
US10/521,411 US20060107338A1 (en) | 2002-07-16 | 2003-07-14 | Hepatic cirrhosis model animal and method of constructing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002207442A JP3964278B2 (ja) | 2002-07-16 | 2002-07-16 | 肝硬変モデル動物およびその作製方法 |
JP2002-207442 | 2002-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004006663A1 true WO2004006663A1 (ja) | 2004-01-22 |
Family
ID=30112819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008939 WO2004006663A1 (ja) | 2002-07-16 | 2003-07-14 | 肝硬変モデル動物およびその作製方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060107338A1 (ja) |
EP (1) | EP1552739A4 (ja) |
JP (1) | JP3964278B2 (ja) |
KR (1) | KR100676010B1 (ja) |
WO (1) | WO2004006663A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3296736A1 (en) | 2016-09-20 | 2018-03-21 | SP Technical Research Institute Of Sweden | Method and system for measuring the energy content of gas |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2500039C1 (ru) * | 2012-07-31 | 2013-11-27 | Александр Михайлович Пузиков | Способ моделирования первичного билиарного цирроза |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602305A (en) * | 1994-03-31 | 1997-02-11 | Yale University | Immunodeficient animal model for studying T cell-mediated immune |
US6034297A (en) * | 1997-09-26 | 2000-03-07 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis C virus |
WO2001005955A2 (en) * | 1999-07-14 | 2001-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Animals comprising human hepatocellular tissue |
US6525242B1 (en) * | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
AU2001256746A1 (en) * | 2000-05-15 | 2001-11-26 | Sonoko Habu | Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof |
-
2002
- 2002-07-16 JP JP2002207442A patent/JP3964278B2/ja not_active Expired - Fee Related
-
2003
- 2003-07-14 KR KR1020057000372A patent/KR100676010B1/ko not_active IP Right Cessation
- 2003-07-14 WO PCT/JP2003/008939 patent/WO2004006663A1/ja active Application Filing
- 2003-07-14 EP EP03741384A patent/EP1552739A4/en not_active Withdrawn
- 2003-07-14 US US10/521,411 patent/US20060107338A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
See also references of EP1552739A4 * |
SEIGO TARAOKA ET AL.: "A novel SCID mouse model for studying spontaneous metastasis of human lung cancer to human tissue", JPN. J. CANCER RES., vol. 86, no. 5, 1995, pages 419 - 423, XP002971841 * |
TASHIO KUDO ET AL.: "Production of a human monoclonal antibody to a synthetic peptide by active in vivo immunization using a SCID mouse grafted with human lymphocytes", TOHOKU J. EXP. MED., vol. 171, 1993, pages 327 - 338, XP002971842 * |
YOSHIO KOYANAGI: "Virus-gaku no atarashii kenkyuho 5. Men'eki fuzen mouse o mochiita virus kansen model", VIRUS, vol. 49, no. 1, 1999, pages 33 - 39, XP002974137 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3296736A1 (en) | 2016-09-20 | 2018-03-21 | SP Technical Research Institute Of Sweden | Method and system for measuring the energy content of gas |
WO2018054905A1 (en) | 2016-09-20 | 2018-03-29 | Sp Technical Research Institute Of Sweden | Method and system for measuring the energy content of gas |
Also Published As
Publication number | Publication date |
---|---|
US20060107338A1 (en) | 2006-05-18 |
JP2004049027A (ja) | 2004-02-19 |
KR20050017104A (ko) | 2005-02-21 |
KR100676010B1 (ko) | 2007-01-30 |
EP1552739A4 (en) | 2007-12-12 |
JP3964278B2 (ja) | 2007-08-22 |
EP1552739A1 (en) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Merrill et al. | Successful transplantation of kidney from a human cadaver | |
Crombleholme et al. | Transplantation of fetal cells | |
US5491284A (en) | Nude mouse model for neoplastic disease | |
Fujinaga et al. | Evidence for an adrenergic mechanism in the control of body asymmetry | |
JP2022510982A (ja) | オルガノイドの生体移植用組成物 | |
JP2021029174A (ja) | ヒト脂肪肝モデル細胞 | |
AU2004238146A1 (en) | Preventive and/or remedy for diseases accompanied by tissue destruction | |
WO2004006663A1 (ja) | 肝硬変モデル動物およびその作製方法 | |
RU2368384C2 (ru) | Биотрансплантат, способ лечения хронических заболеваний печени и способ лечения цирроза печени и портальной гипертензии | |
WO2004045666A1 (ja) | 臓器の再生方法 | |
RU2410761C1 (ru) | Способ моделирования экспериментального амилоидоза у крыс | |
JP2001518934A (ja) | 移植部位としての骨髄 | |
Shikani et al. | Juvenile nasopharyngeal angiofibroma tumor models: failure of androgens to stimulate growth in nude mice and in vitro | |
Ribatti | Protagonists of medicine | |
RU2714949C2 (ru) | Способ моделирования местного отграниченного перитонита у крыс | |
Young | The evolution of ideas about animal hormones | |
WO2004006664A1 (ja) | 非癌部肝臓組織が移植されたモデル動物およびその作製方法 | |
WO2023195429A1 (ja) | 非ヒト動物、及びその利用 | |
WO2017150566A1 (ja) | タンパク質凝集に起因する変性症状を呈する非ヒト動物 | |
CN110384712B (zh) | 核酸适配子在制备治疗阿尔茨海默氏病药物中的应用 | |
KR102552671B1 (ko) | 이식형 약물전달 디바이스 및 이의 용도 | |
McDonald | CONGENITAL SYPHILITIC MESAORTITIS ASSOCIATED WITH ACUTE YELLOW ATROPHY OF THE LIVER: WITH A NOTE ON THE SALVARSAN-LIVER NECROSIS SEQUENCE | |
Kolomeets et al. | Complex phytochemical preparation (Herba centaurii, Radix levistici and Folia rosmarini) Protects Kidney during Glomerulonephritis | |
Anderson et al. | Selected Abstracts on Animal Models for Biomedical Research-III. | |
Burclaff | Defining Gastric Epithelial Cell Population Dynamics At Homeostasis And Following Injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003741384 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057000372 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057000372 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003741384 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006107338 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10521411 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10521411 Country of ref document: US |